Anticoagulant News and Research

RSS

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system.

25 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Voice response system useful for monitoring anticoagulant patients

Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.

27 Apr 2009

New method to estimate bleeding risk in heart attack patients

With eight basic medical facts in hand, doctors can now estimate the risk of bleeding for a patient having a heart attack.

14 Apr 2009

Complementary and alternative medicines can be safe, effective for kids

Today, more children than ever are being treated with complementary and alternative therapies.

6 Apr 2009

Discovery of link between atrial fibrillation and increased risk of death in diabetic patients

Results from a large, international, randomised, controlled trial have shown that there is a strong link between diabetics who have an abnormal heart rhythm (atrial fibrillation) and an increased risk of other heart-related problems and death.

11 Mar 2009

Kidney disease increases risk of stroke in patients with atrial fibrillation

Chronic kidney disease increases the risk of stroke in patients with atrial fibrillation (AF), the most common type of heart arrhythmia, according to a new study by Kaiser Permanente researchers in the current online issue of Circulation.

4 Mar 2009

Kidney disease affects response to anticoagulant drug warfarin

Patients with reduced kidney function require lower doses of the anticoagulant drug warfarin, and may need closer monitoring to avoid serious bleeding complications, suggests a study in the April 2009 issue of the Journal of the American Society of Nephrology ( JASN ).

20 Feb 2009

Study reveals high level of adverse drug reactions in hospitals

In a study of more than 3,000 patients, researchers at the University of Liverpool have found that one in seven admitted to hospital experience adverse drug reactions to medical treatment.

15 Feb 2009

FDA approves orphan drug ATryn anticoagulant

The U.S. Food and Drug Administration has issued its first approval for a biological product produced by genetically engineered (GE) animals.

8 Feb 2009

Entomologists look for Lyme disease answers in tick saliva

In research that could mitigate the spread of Lyme disease, Kansas State University entomologists are looking for answers in tick saliva.

12 Dec 2008

New approaches to prevent blood clots

The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

7 Dec 2008

Idiopathic pulmonary fibrosis linked to heart attacks

Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events - including heart attacks - than people without the disease, according to a recent study that analyzed the risk of cardiovascular disease in nearly 1,000 patients with IPF and more than 3,500 matched controls.

5 Dec 2008

Scientists create synthetic Heparin in more varieties

Scientists at the University of North Carolina at Chapel Hill have learned to customize a key human enzyme responsible for producing heparin, opening the door to a more effective synthetic anticoagulant as well as treatments for other conditions.

25 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

Trial of Gore-tex-type material to stop strokes

A study is under way at Rush University Medical Center using a small, soft-patch device made of a Gore-tex-type material - often used to make durable outerwear - to close a common hole found in the heart called a patent foramen ovale (PFO) in order to prevent recurrent strokes and transient ischemic attacks (TIAs) in adults.

18 Nov 2008